Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments

Kathryn E. Gropp, Cathy S. Carlson, Mark G. Evans, Cedo M. Bagi, William J. Reagan, Susan I. Hurst, David L. Shelton, Mark A. Zorbas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in a partial clinical hold on all NGF inhibitors. Three nonclinical toxicology studies were conducted to evaluate the effects of tanezumab or the murine precursor muMab911 on selected bone and joint endpoints and biomarkers in cynomolgus monkeys, Sprague-Dawley rats, and C57BL/6 mice. Joint and bone endpoints included histology, immunohistochemistry, microcomputed tomography (mCT) imaging, and serum biomarkers of bone physiology. Responses of bone endpoints to tanezumab were evaluated in monkeys at 4 to 30 mg/kg/week for 26 weeks and in rats at 0.2 to 10 mg/kg twice weekly for 28 days. The effects of muMab911 at 10 mg/kg/week for 12 weeks on selected bone endpoints were determined in mice. Tanezumab and muMab911 had no adverse effects on any bone or joint parameter. There were no test article–related effects on bone or joint histology, immunohistochemistry, or structure. Reversible, higher osteocalcin concentrations occurred only in the rat study. No deleterious effects were observed in joints or bones in monkeys, rats, or mice administered high doses of tanezumab or muMab911.

Original languageEnglish (US)
Pages (from-to)408-420
Number of pages13
JournalToxicologic Pathology
Volume46
Issue number4
DOIs
StatePublished - Jun 1 2018

Fingerprint

Biomarkers
Nerve Growth Factor
Haplorhini
Rats
Bone
Joints
Monoclonal Antibodies
Tissue
Bone and Bones
Histology
Replacement Arthroplasties
Immunohistochemistry
X-Ray Microtomography
Macaca fascicularis
Antibodies
Osteocalcin
Physiology
Inbred C57BL Mouse
Chronic Pain
Toxicology

Keywords

  • bone safety
  • joint safety
  • nerve growth factor
  • osteoarthritis
  • tanezumab

Cite this

Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys : Histopathologic, Biomarker, and Microcomputed Tomographic Assessments. / Gropp, Kathryn E.; Carlson, Cathy S.; Evans, Mark G.; Bagi, Cedo M.; Reagan, William J.; Hurst, Susan I.; Shelton, David L.; Zorbas, Mark A.

In: Toxicologic Pathology, Vol. 46, No. 4, 01.06.2018, p. 408-420.

Research output: Contribution to journalArticle

Gropp, Kathryn E. ; Carlson, Cathy S. ; Evans, Mark G. ; Bagi, Cedo M. ; Reagan, William J. ; Hurst, Susan I. ; Shelton, David L. ; Zorbas, Mark A. / Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys : Histopathologic, Biomarker, and Microcomputed Tomographic Assessments. In: Toxicologic Pathology. 2018 ; Vol. 46, No. 4. pp. 408-420.
@article{55b7eb5b7c184967ba4869431a396951,
title = "Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments",
abstract = "Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in a partial clinical hold on all NGF inhibitors. Three nonclinical toxicology studies were conducted to evaluate the effects of tanezumab or the murine precursor muMab911 on selected bone and joint endpoints and biomarkers in cynomolgus monkeys, Sprague-Dawley rats, and C57BL/6 mice. Joint and bone endpoints included histology, immunohistochemistry, microcomputed tomography (mCT) imaging, and serum biomarkers of bone physiology. Responses of bone endpoints to tanezumab were evaluated in monkeys at 4 to 30 mg/kg/week for 26 weeks and in rats at 0.2 to 10 mg/kg twice weekly for 28 days. The effects of muMab911 at 10 mg/kg/week for 12 weeks on selected bone endpoints were determined in mice. Tanezumab and muMab911 had no adverse effects on any bone or joint parameter. There were no test article–related effects on bone or joint histology, immunohistochemistry, or structure. Reversible, higher osteocalcin concentrations occurred only in the rat study. No deleterious effects were observed in joints or bones in monkeys, rats, or mice administered high doses of tanezumab or muMab911.",
keywords = "bone safety, joint safety, nerve growth factor, osteoarthritis, tanezumab",
author = "Gropp, {Kathryn E.} and Carlson, {Cathy S.} and Evans, {Mark G.} and Bagi, {Cedo M.} and Reagan, {William J.} and Hurst, {Susan I.} and Shelton, {David L.} and Zorbas, {Mark A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1177/0192623318772501",
language = "English (US)",
volume = "46",
pages = "408--420",
journal = "Toxicologic Pathology",
issn = "0192-6233",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys

T2 - Histopathologic, Biomarker, and Microcomputed Tomographic Assessments

AU - Gropp, Kathryn E.

AU - Carlson, Cathy S.

AU - Evans, Mark G.

AU - Bagi, Cedo M.

AU - Reagan, William J.

AU - Hurst, Susan I.

AU - Shelton, David L.

AU - Zorbas, Mark A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in a partial clinical hold on all NGF inhibitors. Three nonclinical toxicology studies were conducted to evaluate the effects of tanezumab or the murine precursor muMab911 on selected bone and joint endpoints and biomarkers in cynomolgus monkeys, Sprague-Dawley rats, and C57BL/6 mice. Joint and bone endpoints included histology, immunohistochemistry, microcomputed tomography (mCT) imaging, and serum biomarkers of bone physiology. Responses of bone endpoints to tanezumab were evaluated in monkeys at 4 to 30 mg/kg/week for 26 weeks and in rats at 0.2 to 10 mg/kg twice weekly for 28 days. The effects of muMab911 at 10 mg/kg/week for 12 weeks on selected bone endpoints were determined in mice. Tanezumab and muMab911 had no adverse effects on any bone or joint parameter. There were no test article–related effects on bone or joint histology, immunohistochemistry, or structure. Reversible, higher osteocalcin concentrations occurred only in the rat study. No deleterious effects were observed in joints or bones in monkeys, rats, or mice administered high doses of tanezumab or muMab911.

AB - Tanezumab, an anti-nerve growth factor (NGF) antibody, is in development for management of chronic pain. During clinical trials of anti-NGF antibodies, some patients reported unexpected adverse events requiring total joint replacements, resulting in a partial clinical hold on all NGF inhibitors. Three nonclinical toxicology studies were conducted to evaluate the effects of tanezumab or the murine precursor muMab911 on selected bone and joint endpoints and biomarkers in cynomolgus monkeys, Sprague-Dawley rats, and C57BL/6 mice. Joint and bone endpoints included histology, immunohistochemistry, microcomputed tomography (mCT) imaging, and serum biomarkers of bone physiology. Responses of bone endpoints to tanezumab were evaluated in monkeys at 4 to 30 mg/kg/week for 26 weeks and in rats at 0.2 to 10 mg/kg twice weekly for 28 days. The effects of muMab911 at 10 mg/kg/week for 12 weeks on selected bone endpoints were determined in mice. Tanezumab and muMab911 had no adverse effects on any bone or joint parameter. There were no test article–related effects on bone or joint histology, immunohistochemistry, or structure. Reversible, higher osteocalcin concentrations occurred only in the rat study. No deleterious effects were observed in joints or bones in monkeys, rats, or mice administered high doses of tanezumab or muMab911.

KW - bone safety

KW - joint safety

KW - nerve growth factor

KW - osteoarthritis

KW - tanezumab

UR - http://www.scopus.com/inward/record.url?scp=85047411255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047411255&partnerID=8YFLogxK

U2 - 10.1177/0192623318772501

DO - 10.1177/0192623318772501

M3 - Article

C2 - 29768985

AN - SCOPUS:85047411255

VL - 46

SP - 408

EP - 420

JO - Toxicologic Pathology

JF - Toxicologic Pathology

SN - 0192-6233

IS - 4

ER -